← Back to Search

low dose 5'-azacitidine for Acute Myeloid Leukemia

Phase 2
Waitlist Available
Led By Roni Tamari, MD
Research Sponsored by Memorial Sloan Kettering Cancer Center
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 2 years
Awards & highlights

Study Summary

This trial will be looking at the side effects of this medicine.

Eligible Conditions
  • Acute Myeloid Leukemia
  • Myelodysplastic Syndrome

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~2 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and 2 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
relapse rate
Secondary outcome measures
overall survival
safety

Trial Design

1Treatment groups
Experimental Treatment
Group I: low dose 5'-azacitidineExperimental Treatment1 Intervention
This is a single arm phase II trial to assess the efficacy and confirm the safety of maintenance therapy with 5'-azacitadine compared to historical control after TCD allogeneic hematopoietic stem cell transplant for patients with MDS and AML who are at high risk of relapse.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
low dose 5'-azacitidine
2013
Completed Phase 2
~40

Find a Location

Who is running the clinical trial?

Memorial Sloan Kettering Cancer CenterLead Sponsor
1,934 Previous Clinical Trials
588,772 Total Patients Enrolled
Roni Tamari, MDPrincipal InvestigatorMemorial Sloan Kettering Cancer Center
4 Previous Clinical Trials
110 Total Patients Enrolled

Media Library

Acute Myeloid Leukemia Research Study Groups: low dose 5'-azacitidine

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What is the primary malady that low dose 5'-azacitidine has been found to be efficacious in treating?

"Low dose 5'-azacitidine is most commonly prescribed for cancer treatments. Other pathologies that can be managed with this drug include 20-30% blasts, neutropenia and/or thrombocytopenia, and anemia."

Answered by AI

Could you enumerate the number of locations in which this trial is taking place?

"The trial is available in 7 distinct medical centres, including Memorial Sloan Kettering Bergen (Consent and Follow-up) in Montvale, as well as 4 other locations. Additionally, the study can be accessed from two more sites: Memorial Sloan Kettering at Basking Ridge (Consent and Follow-up) in Basking Ridge and Memorial Sloan Kettering Nassau (Consent and Follow-up) in Rockville Centre."

Answered by AI

What is the aggregate number of individuals involved in this experiment?

"As of now, this particular clinical trial is not able to accept applicants. Initially posted on the first of December, 2013 and most recently updated a decade later in 2022, other trials may be more suitable for your needs. At present there are 2803 studies seeking individuals with leukemia or myeloid disorders; 174 investigations also require low dose 5'-azacitidine participants."

Answered by AI

Is participation in this clinical trial open to the public?

"In order to qualify for the trial, patients must meet three criteria: they need to be diagnosed with myeloid leukemia, between one and seventy-five years of age, and looking to join a cohort of 32 participants."

Answered by AI

Is it possible to volunteer for this trial at the present time?

"Per the information on clinicaltrials.gov, this medical trial is not presently in need of candidates. This investigation was first published on December 1st 2013 and had its last update on December 1 2022. Despite this study’s inactive recruitment status, there are 2977 other trials inviting participants at present."

Answered by AI

Has the FDA sanctioned 5'-azacitidine at small dosages?

"Our team at Power judged the safety of low dose 5'-azacitidine to be a 2, as it is still in Phase 2. This implies that while there are some data suggesting its safety, no evidence exists yet for its efficacy."

Answered by AI

Could you provide a survey of the literature investigating low dose 5'-azacitidine?

"The first exploration of low dose 5'-azacitidine was conducted in 2006 by the Chinese University of Hong Kong-Prince of Wales Hospital. There are now 174 active trials, with a number of them situated near Montvale, New york, and 160 studies that have been completed."

Answered by AI

Does this clinical trial permit participants who are younger than 25 years old?

"Patients need to be between 1 and 75 years old in order meet the criteria for enrollment into this clinical trial."

Answered by AI
Recent research and studies
clinicaltrials.govStudy
Maintenance Low Dose 5'-Azacitidine Post T Cell Depleted Allogeneic Stem Cell Transplantation for Patients With Myelodysplastic Syndrome and Acute Myelogenous Leukemia With High Risk for Post-Transplant Relapse
2013. "Maintenance Low Dose 5'-Azacitidine Post T Cell Depleted Allogeneic Stem Cell Transplantation for Patients With Myelodysplastic Syndrome and Acute Myelogenous Leukemia With High Risk for Post-Transplant Relapse". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT01995578.
~3 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top